#	Pagina
attuale pagina	/open-h2020/projects/209445/index.html

Opendata, web and dolomites

EBOVAC2 SIGNED

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EBOVAC2 project word cloud

Explore the words cloud of the EBOVAC2 project. It provides you a very rough idea of what is the project "EBOVAC2" about.

placebo mva confirm ad26 characterising ebovac stakeholders protection ages locations ebola humans individuals perform wp4 preparation population compressed translational data soon filo africa capacity immunogenicity zebov begin special repository carefully volunteers 17 wp5 primates ebovac2 safety elicited bn communicating community staff intended children hiv human countries disseminating boosting enrolment monitoring elderly link wp3 vaccine 65 immune groups trials african wp2 centres vaccinated wp6 500 infected subjects efficacy nature infrastructure central approximately extensive ebovac1 parallel

Project "EBOVAC2" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.ebovac2.com/
Total cost	50˙710˙893 €
EC max contribution	22˙790˙820 € (45%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2014-02-single-stage
Funding Scheme	IMI2-RIA
Starting year	2014
Duration (year-month-day)	from 2014-12-01 to 2020-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	15˙650˙912.00
2	CENTRE MURAZ CENTRE MURAZ Organization address address: Avenue Mamadou Konate city: BOBO-DIOULASSO postcode: NA website: http://membres.lycos.fr/centremuraz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BF (BOBO-DIOULASSO)	participant	3˙782˙783.00
3	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	2˙041˙083.00
4	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER Organization address address: KEPPEL STREET city: LONDON postcode: WC1E 7HT website: http://www.lshtm.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	888˙951.00
5	INSERM - TRANSFERT SA INSERM - TRANSFERT SA Organization address address: RUE WATT 7 city: PARIS postcode: 75013 website: www.inserm-transfert.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	427˙090.00
6	JANSSEN VACCINES & PREVENTION BV JANSSEN VACCINES & PREVENTION BV Organization address address: ARCHIMEDESWEG 4 city: LEIDEN postcode: 2333 CN website: www.crucell.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	0.00

Map

Project objective

The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.

This will be done by: 1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4) 2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II studies will be conducted in parallel with the planned Phase III study (EBOVAC1). The phase II studies will be placebo-controlled and will be conducted in locations where it is possible to perform carefully controlled safety studies (via WP2). 3. Evaluating the use of the vaccine in special population groups, such as children (ages 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase II trials will begin as soon as safety data are available from Phase I trials (via WP2). 4. Monitoring and characterising immune response to the proposed vaccine (via WP3). 5. Boosting the capacity of African centres, staff and infrastructure in preparation for Phase III studies and communicating and disseminating widely the results of EBOVAC2 as they become available to all key stakeholders (via WP6). 6. Contributing all data to the Central Information Repository for use by other Ebola programme projects as well as the wider community (via WP5).

Deliverables

List of deliverables.
Capacity-building implementation report	Documents, reports	2019-11-15 10:09:23
1st EBOVAC2 e-newsletter	Other	2019-11-15 10:09:23
Communication tools	Other	2019-11-15 10:09:23
Ebola project clustering activity plan	Documents, reports	2019-11-15 10:09:23
Capacity-building programme	Documents, reports	2019-11-15 10:09:23

Take a look to the deliverables list in detail: detailed list of EBOVAC2 deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2016	Barry H, ValÃ©a I, BerthÃ© A, LouguÃ© G, Tinto H, ThiÃ©baut R, et al. 1-BarriÃ¨res et facilitateurs de la mise en oeuvre dâ€™un essai vaccinal en situation dâ€™urgence: cas de lâ€™essai EBOVAC2 au Burkina Faso.2- Barriers and facilitators in implementin g a vaccine trial in emergency situation: the case of EBOLA Vaccine Phase II Trial (VAC52150 EBL2002) in Burkina Faso published pages: , ISSN: , DOI:	3-6 may 2016; 26 to 28 May 2016	2019-11-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOVAC2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOVAC2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors